Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Dupilumab1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬8件: 51, 97, 98, 160, 162, 222, 300, 306 💬
2Dupilumab (blinded)1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98 💬
3Dupilumab (open-label)1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98 💬
4Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 98 💬
5Dupilumab 300Mg Solution for Injection1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 51 💬
6Dupilumab Injection1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 160 💬
7Dupilumab open label extension phase1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 222 💬
8Dupilumab Prefilled Syringe1件: Dupilumab (Dupilumab)1件: Dupilumab (Dupilumab) 💬 1件: IL4R 💬 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 160 💬
9Secukinumab was administered in a weight-adapted dosing regimen ? Dupilumab was administered at a dose dependent on the patient's weight and age2件: Dupilumab (Dupilumab),
Secukinumab		2件: Secukinumab ,
Dupilumab (Dupilumab) 💬 		2件: IL17A,
IL4R 💬 		11件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬1件: 160 💬